Physician profile
Dmitry Sukenik
NPI 1811985443
$7,852.38
in general payments reported to CMS, 2019-2025
37 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $465 · 2021: $1,351 · 2022: $1,308 · 2023: $1,259 · 2024: $1,060 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377 · Travel and Lodging: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.97 |
| Travel and Lodging | $696.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,087.77 | 2019-2025 | |
| Philips North America LLC | $1,058.14 | 2022-2025 | Igt Devices Undivided, Intrasight Integrated |
| Janssen Pharmaceuticals, INC | $806.00 | 2019-2024 | Xarelto, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $686.64 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $601.19 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $561.44 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $444.08 | 2019-2025 | Farxiga |
| Pfizer INC. | $397.23 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $355.65 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $219.00 | 2021-2023 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $171.80 | 2022-2025 | Watchman Flx |
| Penumbra, INC. | $147.14 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $123.23 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $115.62 | 2019-2022 | |
| Astellas Pharma US INC | $114.73 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $106.93 | 2023-2024 | Inpefa |
| Shockwave Medical, INC | $101.08 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $93.14 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abiomed | $84.98 | 2023-2025 | Impella |
| Amgen INC. | $68.53 | 2019-2025 | Repatha |
| Chiesi USA, INC. | $65.97 | 2021-2024 | Kengreal, Cleviprex |
| Kiniksa Pharmaceuticals, LTD. | $60.36 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $43.25 | 2024-2025 | |
| Abbott Laboratories | $43.22 | 2022-2023 | Xience Sierra |
| Surmodics, INC. | $32.91 | 2023 | Pounce Venous Thrombectomy System, Pounce Thrombectomy System, Pounce Thrombectomy |
| Corcept Therapeutics | $29.97 | 2025 | Korlym |
| Smith+Nephew, INC. | $29.61 | 2025 | Collagenase Santyl |
| Angiodynamics, INC. | $29.16 | 2024 | Alphavac |
| Inspire Medical Systems, INC. | $21.77 | 2023 | Inspire |
| Livanova USA, INC. | $21.61 | 2022 | |
| Medtronic, INC. | $20.78 | 2024 | Hawkone |
| Glaxosmithkline, LLC. | $20.11 | 2021 | |
| Terumo Medical Corporation | $20.01 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.33 | 2025 | Onpattro |
| Exact Sciences Corporation | $19.04 | 2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $16.55 | 2024 | Zio Xt Patch, Zio Monitor |
| Cardinal Health 200 LLC | $14.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitry Sukenik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.